covid
Buscar en
Porto Biomedical Journal
Toda la web
Inicio Porto Biomedical Journal GE11 positive exosomes as a potential RNAi delivery system in clear cell Renal C...
Journal Information
Vol. 2. Issue 5.
Pages 181 (September - October 2017)
Share
Share
Download PDF
More article options
Vol. 2. Issue 5.
Pages 181 (September - October 2017)
PS081
Open Access
GE11 positive exosomes as a potential RNAi delivery system in clear cell Renal Cell Carcinoma
Visits
1802
B. Adem1,
Corresponding author
badem@ipatimup.pt

Corresponding author.
, A.L. Teixeira2,3, F. Dias2,3, C. Ruivo1, R. Medeiros2,3,4,5,*, S.A. Melo1,5,*
1 Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal (i3S), 4200 Porto, Portugal, Institute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP), 4200 Porto, Portugal
2 Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072 Porto, Portugal
3 LPCC, Research Department Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro-Núcleo Regional do Norte), 4200-177 Porto, Portugal
4 Health Sciences Faculty, Fernando Pessoa University, 4249-004, Porto, Portugal
5 FMUP, Medical Faculty of the University of Porto, Portugal
This item has received

Under a Creative Commons license
Article information
Full Text

Aim: Use GE11 positive (GE11+) exosomes as a targeted delivery system to EGFR overexpressing cells for the treatment of clear cell Renal Cell Carcinoma (ccRCC).

Introduction: ccRCC is the most prevalent subtype of renal cancer and the most lethal urologic tumor. Generally, it is radio-chemotherapy resistance, and frequently associated with relapse after 5–11 months upon targeted therapy treatment, which highlight the need to develop new therapeutic strategies. Exosomes, extracellular vesicles of 40–150nm that mediate intercellular communication, have emerged as promising therapeutic tools due to their engineering potential and ability to evade the immune system.

Methods: EGFR is known to be overexpressed in ccRCC thus, the expression of GE11, a peptide that binds to EGFR, in exosomes membrane enable a targeted delivery of therapeutic molecules to EGFR overexpressing cells. Exosomes derived from HEK293T were engineered to express the GE11 peptide on their surface and incubated with normal or tumor renal cell lines.

Results: Our results revealed EGFR overexpression at the mRNA and protein levels in a ccRCC cell line, compared to a normal renal cell line. Furthermore, tumor cells presented increased protein levels of phosphorylated EGFR when compared to normal cells. These results support the hypothesis of using an EGFR-based exosomes delivery model, the GE11+ exosomes. A higher percentage of tumor cells internalized GE11+ exosomes compared to exosomes derived from HEK293T cells transfected with control condition. Additionally, tumor cells exhibited an increased mean of fluorescence intensity compared to the control, suggesting that each cell uptakes more GE11+ exosomes in an EGFR-dependent manner. Importantly, GE11+ exosomes were internalized in a greater proportion by tumor cells rather than normal renal cell lines.

Conclusion: Overall, the use of GE11+ exosomes as a new delivery system is a promising therapeutic strategy for ccRCC treatment. Ultimately, these exosomes can be loaded with RNAi-based drugs to target deregulated genes in ccRCC.

Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos